RDHL · Categories · M&A
RDHL - Mergers and acquisitions
Redhill Biopharma Ltd. (RDHL) mergers and acquisitions - real-time wire coverage filtered to M&A only.
Recent M&A for RDHL
- CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIOCumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy NASHVILLE, Tenn., Oct. 20, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced strategic arrangements with RedHill Biopharma Ltd. (NASDAQ:RDHL), a specialty biopharmaceutical company, to jointly commercialize Talicia®. The FDA-approved oral capsule is indicated for the treatment of Helicobacter pylori infection in adults, a bacterial infection and leading risk factor for gastric cancer.
- RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership DealCumberland Pharmaceuticals Inc. (NASDAQ:CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill's Talicia business U.S. co-commercialization partnership designed to accelerate Talicia sales growth, leveraging Cumberland's expanded national sales promotion and marketing support, and deliver significant efficiencies through shared operational responsibility Transaction reinforces RedHill's financial position to advance its broader strategic objectives Patent protected through 2042 and with eight years QIDP market exclusivity, Talicia is:The #1 branded U.S. gastroenterologist-prescribed H. pylori therapy1 Listed first-line H. pylori therapy in American Colle